Panamor
2-[2-(2,6-Dichloroanilino)phenyl]acetic acid
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 3033.
Registration
- Applicants
- 1
- Registrations
- 7
- Schedule source
- SAHPRA documentation
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Panamor suppositories - 12,5 EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 12,5 mg | - 12,5Suppositories | 27012127/3.1/0121 | Registered | Not determined | None |
| Panamor patch EACH PLASTER CONTAINS DICLOFENAC EPOLAMINE EQUIVALENT TO DICLOFENAC 0,130 g | Patch | 33009133/3.1/0091 | Registered | Not determined | None |
| Panamor 50 MG dispersible tablet EACH TABLET CONTAINS DICLOFENAC 46,5 mg | 50 mgDispersible tablet | A380383A38/3.1/0383Approved 24 October 2025 | Registered | S2 | PIPIL |
| Panamor - 25 EACH TABLET CONTAINS DICLOFENAC SODIUM 25 MG | 25 mgFilm-coated tablets | R0049R/3.1/49Approved 29 November 2021 | Registered | S2 | PIPIL |
| Panamor - 75 injection EACH 3 ml AMPOULE CONTAINS DICLOFENAC SODIUM 75 ml | - 75Injection | W0052W/3.1/52 | Registered | Not determined | None |
| Panamor suppositories EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 100 mg | Suppositories | Y0395Y/3.1/395 | Registered | Not determined | None |
| Panamor suppositories - 25 EACH SUPPOSITORY CONTAINS DICLOFENAC SODIUM 25,0 mg | - 25Suppositories | Z0172Z/3.1/172 | Registered | Not determined | None |
Regulatory status
Where S2 sits on the scale
A pharmacist can sell it directly, without a prescription.
Schedule 2 medicines sit behind the pharmacy counter. A pharmacist can decide to sell one of these directly, using their own professional judgement, without a doctor's prescription. It can also be dispensed against a prescription like the higher tiers, in which case the usual repeat limits apply. A child under 12 may only be sold a Schedule 2 substance on a prescription, or on a written order that names the purpose and carries a signature the seller recognises. Even though it cannot be advertised to the public in the ordinary sense, its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.
Schedule S2, read from the product's PI-PIL leaflet.
The Consolidated Schedules list this ingredient up to S3; the leaflet's S2 applies to this product.
Who may supply: Only a pharmacist, pharmacist intern or supervised pharmacist's assistant may sell it without a prescription. It may otherwise be dispensed by a pharmacist against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Diclofenac
S3: Diclofenac
- except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
- except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1)
- except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2)
- except when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days. (S2)
Consolidated Schedules 06 July 2026, lines 3415 to 3427
S2: Diclofenac
- when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S3)
- when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 days;
- except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
- except when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S1)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 1807 to 1821
S1: Diclofenac
- when intended for application to the skin and containing more than 1 % m/m of diclofenac; (S3)
- except when intended for application to the skin and containing 1 % m/m or less of diclofenac subject to a maximum pack size of 50 grams; (S0)
- except when intended for the emergency treatment of acute gout attacks, subject to a maximum daily dose of 150 mg for a maximum treatment period of 3 days; (S2)
- except when intended for human use only in the treatment of fever or mild to moderate pain of inflammatory origin, or for the treatment of post-traumatic conditions, subject to a maximum daily dose of 75 mg for a maximum treatment period of 5 day; (S2)
- except when intended for veterinary use. (S3)
Consolidated Schedules 06 July 2026, lines 365 to 379
Pharmacological class: Antirheumatics (anti-inflammatory agents). (class 3.1)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
Schedule Verification
Panamor 50 MG dispersible tablet, Pharmacare limited û woodmead is scheduled S2 in its official SAHPRA documents, read with 90% confidence.
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.